For patients with core binding factor AML, for instance, LSCs characterized as CD34+CD38−ALDHint represent a minute fraction of the tumor at diagnosis, but are enriched in CR, with their presence predicting disease relapse [79]. Here, CD34 is linked to acute myeloid leukemia.